An interventional study of Remimazolam bolus and Remimazolam continuous in Hypotension on Induction, sponsored by Kangbuk Samsung Hospital. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-06-02.
Sponsored by Kangbuk Samsung Hospital · Not applicable, Interventional, and Other
Remimazolam is a newly introduced intravenous anesthetic, with rapid onset and offset. Although it is known to cause less hemodynamic instability, the incidence hypotension is the one of the most frequent adverse events with its use. For anesthetic induction, remimazolam can be used either as bolus dose or as continuous infusion.
This study is aimed to investigate the incidence of hypotension after anesthetic induction with bolus (0.14-0.33 mg/kg) or continuous (12 mg/kg/hr) remimazolam administration.
Exclusion Criteria:
Anesthetic induction with bolus remimazolam administration
Drug: Remimazolam bolus
Anesthetic induction with continuous remimazolam administration
Drug: Remimazolam continuous
Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, \<40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, \>80 years
Remimazolam 12 mg/kg/hr
Incidence of hypotension
Systolic pressure below 90 mmHg
Time frame: 10 minutes after anesthetic induction
Incidence of bradycardia
heart rate below 40 beats per minute
Time frame: 10 minutes after anesthetic induction
The lowest systolic blood pressure
The lowest systolic blood pressure
Time frame: 10 minutes after anesthetic induction
Number of participants with vasoactive drug use
Use of vasoactive drug for the blood pressure or the heart rate management
Time frame: 10 minutes after anesthetic induction
Time to loss of consciousness
Time from drug administration to loss of consciousness
Time frame: 10 minutes after anesthetic induction
Dosage of remimazolam
Total dose or remimazolam used for anesthetic induction
Time frame: 10 minutes after anesthetic induction
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kangbuk Samsung Hospital